Sustainability at Biocon

Growing participation in global biosimilars market PARTNER BBL ROLE Mylan® VIATRIS (2009) SANDOZA Novartis (2018) Division Biosimilars co-developed and co-commercialized with R&D and manufacturing led by BBL Set of next-gen biosimilars being co-developed Biocon Biologics Transforming Healthcare. Transforming Lives. (ONGOING) Independently developing several biosimilar assets Acquisition of Viatris' biosimilar business to build a fully-integrated global biosimilar enterprise Biocon 1 BBL ECONOMICS Collaboration with partners to build complementary capabilities, de-risking the journey in an uncharted territory 15

View entire presentation